REG - ReNeuron Group plc - ReNeuron presents in vivo data at Cell 2023

ReNeuronAnnouncement

08/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231108:nRSH6891Sa&default-theme=true

RNS Number : 6891S  ReNeuron Group plc  08 November 2023

 

ReNeuron Group plc

("ReNeuron" or "the Group")

 

ReNeuron presents in vivo data at Cell 2023

 

In vivo data highlights the specific tissue and cellular targeting
capabilities

of ReNeuron's stem cell derived exosome drug delivery platform, CustomEX(TM)

 

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome
technologies, announces that Dr Samantha Thomas will be presenting in vivo
data exemplifying the cellular and tissue targeting capabilities and
highlighting the significant advantages of ReNeuron's CustomEX™ drug
delivery platform, at Cell 2023 in London.

 

Key highlights from the presentation entitled Targeted Delivery of Therapeutic
Payloads Using Stem Cell derived Exosome include:

 

·    Confirmation in vitro and in vivo that exosome targeting is
dependent on cell source and selection of a specific exosome population
results in the improved delivery of therapeutic payloads when compared to a
conventional HEK293 exosome approach.

·    A specific CustomEX™ exosome targets the lymph nodes (immune
system) proportionately more than other exosome types.

·    A specific CustomEX™ exosome selectively targets the tubules
within the kidney.

·    A specific CustomEX™ exosome targets the lung following systemic
administration.

·    Confirmation that therapeutic payloads can be successfully delivered
in vivo using the CustomEX™ platform following systemic administration.

·    No evidence of immune response or toxicity with any of the exosome
candidates, opening up the possible use of CustomEX™ for repeat
administration unlike viral vectors.

 

These data highlight the significant improvement in targeting and delivery of
payloads that can be achieved through the careful selection of specific
exosomes from different cell sources. ReNeuron's CustomEX(TM) platform, is a
compelling platform that offers this ability to select the exosome cell type
for a partner's need and the payload / target cell of their choice, while
offering a scalable and repeatable manufacturing process due to its patented
conditional immortalisation technology. This technology was enabled through
the Group's earlier work in producing GMP stem cells approved by the FDA and
MHRA for the clinic from which the Group's exosomes are now produced.

 

The presentation from the conference will also be available on the ReNeuron
website after the event: https://www.reneuron.com/investors/presentations/
(https://www.reneuron.com/investors/presentations/)

 

CustomEX(TM) is a register trademark of ReNeuron Limited.

 

Enquiries:

 

 ReNeuron                                                www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                           Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser and Broker)  +44 (0)20 3328 5656
 James Reeve / George Payne /

 Dan Dearden-Williams (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                         (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings                           +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Group can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business
achievements/performance of ReNeuron and certain of the plans and objectives
of management of ReNeuron with respect thereto. These statements may
generally, but not always, be identified by the use of words such as "should",
"expects", "estimates", "believes" or similar expressions. This announcement
also contains forward-looking statements attributed to certain third parties
relating to their estimates regarding the growth of markets and demand for
products. By their nature, forward-looking statements involve risk and
uncertainty because they reflect ReNeuron's current expectations and
assumptions as to future events and circumstances that may not prove accurate.
A number of factors could cause ReNeuron's actual financial condition, results
of operations and business achievements/performance to differ materially from
the estimates made or implied in such forward-looking statements and,
accordingly, reliance should not be placed on such statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUBONRONUARAA